

Αποτελέσματα προκηρύξεων 2012

Δρ. Σ. Κολυβά

Αναπληρώτρια Εθνική Εκπρόσωπος
Ελληνικό Ινστιτούτο Παστέρ

WP 2012: 2 προκηρύξεις


— FP7-HEALTH-INNOVATION-1

- Κύρια προκήρυξη: 34 θέματα
- Ενδεικτικός προϋπολογισμός €572.1m

• FP7-HEALTH-INNOVATION-2

- Ειδική προκήρυξη: 3 θέματα
- Ενδεικτικός προϋπολογισμός €86.56m

Ποσοστό αξιολογητών από Ιδ.Τομέα



FP7-HEALTH-2012-Innovation-2


- Καταληκτική ημερομηνία Σταδίου 1 : 27 Σεπτεμβρίου 2011
κατατέθηκαν προτάσεις **112**
- Αξιολόγηση τον Οκτώβριο . Ειδοποίηση στις 28 Οκτωβρίου για
κατάθεση σε β' στάδιο (**46 προτάσεις**)
- Στάδιο 2 καταληκτική ημερομηνία 13 Δεκεμβρίου 2011
=> υποβλήθηκαν **45 προτάσεις, απεσύρθη 1 πρόταση**
- Αξιολόγηση 20 Δεκεμβρίου– 20 Ιανουαρίου, ειδοποίηση προς τους
συντονιστές, 9 Φεβρουαρίου 2012.
- Αποτέλεσμα : ~19 προτάσεις προτείνονται για χρηματοδότηση
(42%)

FP7-HEALTH-2012-Innovation-1


Στάδιο 1 καταληκτική ημερομηνία 4 Οκτωβρίου 2011, υποβλήθηκαν **1173** προτάσεις

- Αξιολόγηση : Μέσα Οκτωβρίου –τέλος Νοεμβρίου, ειδοποίηση: ~7-8 Δεκεμβρίου, **322** προχώρησαν στο στάδιο 2 (**27.5%**)
- Στάδιο 2 καταληκτική ημερομηνία 8 Φεβρουαρίου 2012
=> **321** προτάσεις, **1** αποσύρθηκε και **2** μη επιλέξιμες
- Αξιολόγηση μέσα Φεβρουαρίου –τέλος Μαρτίου , ειδοποίηση 20 Απριλίου 2012
- Αποτελέσμα : 121 προτείνονται για χρηματοδότηση (38%)


Αριθμός προτάσεων




Αριθμός προτάσεων που αξιολογήθηκαν



Φορείς που συμμετέχουν




Αριθμός ΜΜΕ




Συμμετοχή κρατών EU27


■ Evaluated
■ Short-listed




Country participation Associated Countries



Country participation Third Countries



Country participation Coordinators



1: Biotechnology, generic tools and technologies

- 1.1 High-throughput research
- **1.2 Detection, diagnosis and monitoring**
- 1.3 Predicting suitability, safety and efficacy of therapies
- 1.4 Innovative therapeutic approaches and interventions

FP7-HEALTH-INNOVATION-1

Area 1.2

Αποτελέσματα αξιολόγησης:

- 1 θέμα
- Ενδεικτικός προϋπολογισμός: €85 M
- Προϋπολογισμός χρηματοδότησης: €73.3 M
- Χρηματοδοτούνται όλες οι προτάσεις που βαθμολογήθηκαν πάνω από τη βάση
- Συνολική βαθμολογία 12.0

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 προκρίθηκαν	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Προς χρηματοδότηση (success rate)	reserve
195	36 (18%)	36	14	14 (39%)	0

rank	score	Coordinator	Acronym	Title	Proposed (EUR)	Cumulative budget
1	14.5	<i>IMMATICS Biotechnologies GmbH</i>	GAPVAC	Glioma Actively Personalized Vaccine Consortium	5,970,450	5,970,450
2	13.5	<i>Sapiens Steering Brain Stimulation B.V.</i>	IMPACT	Improving the lives of Parkinson's Disease patients while reducing side-effects through tailored deep brain stimulation	4,980,907	10,951,357
3	13	<i>INSTITUT CURIE</i>	RAIDs	Rational molecular Assessments and Innovative Drug Selection	5,999,643	16,951,000
4	12.5	<i>ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA</i>	NGS-PTL	Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia	5,870,815	22,821,815
5	12.5	<i>CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE</i>	BIOMS	Biological markers for rationalizing treatment decisions in Multiple Sclerosis (MS)	4,880,576	27,702,391
6	12.5	<i>UNIVERSITA DEGLI STUDI DI FERRARA</i>	THALAMOSS	THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia	5,020,000	32,722,391
7	12.5	<i>BIOMEDICAL RESEARCH FOUNDATION, Academy of Athens</i>	RiskyCAD	Personalized diagnostics and treatment of high risk coronary artery disease patients.	5,992,102	38,714,493
8	12.5	<i>UNIVERSITEIT TWENTE</i>	CTCtrap	Circulating Tumor Cells Therapeutic Apheresis: a novel biotechnology enabling personalized therapy for all cancer patients	6,000,000	44,714,493
9	12.5	<i>UNIVERSITY COLLEGE CORK</i>	IMPROVED	IMproved Pregnancy Outcomes by Early Detection; personalized medicine for pregnant women: novel metabolomic and proteomic biomarkers to detect pre-eclampsia and improve outcome.	5,997,671	50,712,164
10	12	<i>STICHTING KATHOLIEKE UNIVERSITEIT</i>	ASSURE	Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation	5,609,671	56,321,835
11	12	<i>UNIVERSITY COLLEGE LONDON</i>	EPI-FEM-CARE	Epigenetics for female personalised cancer care	5,875,387	62,197,222
12	12	<i>FRAUNHOFER</i>	IACOBUS	Diagnosis and Monitoring of Inflammatory and Arthritic diseases using a Combined approach Based on Ultrasound, optoacoustic and hyperSpectral imaging	3,046,476	65,243,698
13	12	<i>OnkoTec GmbH</i>	DIPROMON	Multimodular biomarker analysis workflow for diagnosis, prognosis and monitoring of drug treatment response in bladder cancer	3,496,394	68,740,092
14	12	<i>POLITECNICO DI MILANO</i>	INSERT	Development of an integrated SPECT/MRI system for enhanced stratification of brain tumour patients prior to patient-specific radio-chemo therapy and early assessment of treatment efficacy	4,600,000	73,340,092

Area 1.2

- Παρατηρήσεις
- Ορισμένες τεχνικά δυνατές προτάσεις είχαν «αδύναμα» στοιχεία κλινικά (π.χ. κλινική αξιολόγηση) και συχνά το αντίστροφο
- Προτάθηκαν προς χρηματοδότηση και οι 14 προτάσεις που είχαν βαθμολογηθεί με πάνω από τη βάση

1: Biotechnology, generic tools and technologies

- 1.1 High-throughput research
- 1.2 Detection, diagnosis and monitoring
- 1.3 Predicting suitability, safety and efficacy of therapies
- **1.4 Innovative therapeutic approaches and interventions**

FP7-HEALTH-INNOVATION-1

Area 1.4

- Αποτέλεσμα της αξιολόγησης:
 - 3 θέματα
 - Ενδεικτικός προϋπολογισμός : €42 M
 - Προϋπολογισμός για χρηματοδότηση €50.16 M
 - Κατώτερη βαθμολογία 13.0
(πολλές προτάσεις σε reserve list)

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 προκρίθηκαν	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
92	23 (25%)	23	12	9 (39%)	3

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14.5	<i>CHARITE - UNIVERSITAETSMEDIZIN BERLIN</i>	BIO-DrIM	Personalized minimization of immunosuppression after transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation	5,989,000	5,989,000
2	14	<i>UNIVERSITAETSKLINIKUM AACHEN</i>	TargetAMD	Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)	5,989,033	11,978,033
3	14	<i>ACADEMISCH ZIEKENHUIS LEIDEN</i>	EUROSTAM	A Europe-wide Strategy to enhance Transplantation of sensitized patients on basis of Acceptable HLA Mismatches.	1,621,500	14,601,533
4	13.5	<i>UNIVERSITY OF OXFORD</i>	COPE	Consortium on Organ Preservation in Europe	5,990,843	20,592,376
5	13.5	<i>UNIVERSITY OF MANCHESTER</i>	ATTACK	Adoptive engineered T cell Trials to Achieve Cancer	6,000,000	26,592,376
6	13.5	<i>UNIVERSITY COLLEGE LONDON</i>	ONSKIP-NMD	A phase I/IIa clinical trial in Duchenne muscular dystrophy systemically delivered morpholino antisense oligomer to skip exon 53	6,182,781	32,775,157
7	13	<i>ACADEMISCH ZIEKENHUIS LEIDEN</i>	STELLAR	Stem-cell based therapy for kidney repair	5,998,050	38,773,207
8	13	<i>UNIVERSITY COLLEGE LONDON</i>	ONEVERREST	Does vascular endothelial growth factor gene therapy improve outcome in severe early-onset fetal growth restriction?	5,998,984	44,772,191
9	13	<i>THE UNIVERSITY OF NOTTINGHAM</i>	HepaMab	Human monoclonal antibody therapy to prevent hepatitis reinfection of liver transplants: advancing lead monoclonal antibodies into clinical trial	5,985,903	50,758,094
10	12.5	<i>INSERM</i>	BIOMARGIN	Biomarkers of renal graft injuries in kidney allograft recipients	6,000,000	Reserve
11	12.5	<i>MEDIZINISCHE HOCHSCHULE HANNOVER</i>	Uni_Cell	Production of antigen-free platelets for universal use	4,719,000	Reserve
12	12	<i>KATHOLIEKE UNIVERSITEIT LEUVEN</i>	EUROBAL	European Translational research to tackle chronic rejection lung transplantation	5,999,999	Reserve

FP7-HEALTH-INNOVATION-2

Area 1.4 - Topic 1.4-2 Medical technology for transplantation and bioartificial organs

Αποτέλεσμα της αξιολόγησης:

- Ενδεικτικός προϋπολογισμός: €42m
- Προϋπολογισμός που θα διατεθεί: €26.3m
- Τελευταία πρόταση: συνολική βαθμολογία 12.0
(όλες οι προτάσεις με βαθμολογία πάνω από τη βάση χρηματοδοτούνται)
- Καλύφθηκαν όλα τα θέματα

Στάδιο1 Υποβλήθηκαν	Στάδιο 1 Επιλέξιμες	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (ποσοστό επιτυχίας)	reserve
33	14 (42%)	14	5	5 (15%)	0

Short list

1.4 (INNO-2)

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	12	<i>Academisch Medisch Centrum bij de Universiteit van Amsterdam</i>	BALANCE	Development of a bioartificial liver therapy in acute liver failure	5,996,180	5,996,180
2	12	<i>NATIONAL UNIVERSITY OF IRELAND, GALWAY</i>	NeuroGraft	Development of Functionalised Cell Seeded Bioartificial Organ for Transplantation in Nerve Repair	4,481,173	10,477,353
3	12	<i>NOVALUNG GMBH</i>	AmbuLung	Ambulatory Bio-Artificial Lung	5,650,000	16,127,353
4	12	<i>DANMARKS TEKNISKE UNIVERSITET</i>	NanoBio4Trans	A new nanotechnology-based paradigm for engineering vascularised liver tissue for transplantation	5,968,093	22,095,446
5	12	<i>MEDICYTE GMBH</i>	Re-Liver	Bottom-up reconstitution of a biomimetic bioartificial liver	4,234,877	26,330,323

INNOVATION-2 – Area 1.4.2

Παρατηρήσεις

- **Η επιτροπή της αξιολόγησης αποτελείτο από 8 CEO/CSOs (2 από ΗΠΑ με εμπειρία από SBIR)**
- **ΟΙ καλύτερες βαθμολογίες (4+4+4).**
- **«Οδηγίες από τους κριτές:**
 - Καλύτερη εξήγηση του πλάνου αξιοποίησης των αποτελεσμάτων
 - Σαφής διαφοροποίηση της βιομηχανικής έρευνας από την ακαδημαϊκή έρευνα
 - Θα πρέπει να υπάρχει ειδικό έντυπο για το αυτό το χρηματοδοτικό σχήμα

2. Translating research for human health

- **2.1 Integrating biological data & processes: large-scale data gathering, systems biology**
- 2.2 Research on the brain and related diseases, human development and ageing
- 2.3 Translational research in major infectious diseases
- 2.4 Translational research in other major diseases

FP7-HEALTH-INNOVATION-1

Area 2.1.1.1

Αποτέλεσμα της αξιολόγησης:

- Ενδεικτικός προϋπολογισμός: €38 m
- Προϋπολογισμός που θα διατεθεί: €38 m
- Τελευταία πρόταση: συνολική βαθμολογία 12.0
(αρκετές προτάσεις σε reserve list)
- Καλύφθηκαν και τα 3 θέματα

Στάδιο 1 Υποβλήθηκαν	Στάδιο 1 επιλέξιμες	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (ποσοστό επιτυχίας)	reserve
44	15 (38%)	15	10	4 (27%)	6*

Short list

Area 2.1.1.1

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	15	<i>UNIVERSITAETSKLINIKUM HEIDELBERG</i>	EURenOmics	European Consortium for High-Throughput Research in Rare Kidney Diseases	11,994,567	11,994,567
2	14.5	<i>EBERHARD KARLS UNIVERSITAET TUEBINGEN</i>	Neuromics	Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases	12,000,000	23,994,567
3	13.5	<i>UNIVERSITY OF NEWCASTLE UPON TYNE</i>	RD-Connect	RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research	11,997,111	35,991,678
4	12	<i>INSERM</i>	SUPPORT-IRDiRC	Support for international rare disease research to serve the IRDiRC objectives	2,000,000	37,991,678
5	14	<i>THE UNIVERSITY OF MANCHESTER</i>	EuroSkelDis	A European omics knowledge factory for the improved diagnosis and therapy of genetic Skeletal Diseases	11,998,716	Reserve
6	13.5	<i>STICHTING KATHOLIEKE UNIVERSITEIT</i>	OMICS-ID	Rare diseases, omics profiles, Intellectual Disability, deep phenotyping, exome sequencing, Open Innovation Platform, clinical utility	11,998,118	Reserve
7	13.5	<i>CHARITE - UNIVERSITAETSMEDIZIN BERLIN</i>	RDCODE	Rare Disease Computing, Omics, Databasing, and eHealth	11,998,230	Reserve
8	12.5	<i>UNIVERSITAET ZU LUEBECK</i>	Care-DSD-omics	Consortium on Adrenal and Reproductive Endocrinology – A systematic application of -omics for Disorders of Sex Development	11,999,112	Reserve
9	12.5	<i>Erasmus MC-Sophia Children's Hospital</i>	o4kids	Omics for kidney tumors in kids	11,996,351	Reserve
10	12	<i>UPPSALA UNIVERSITET</i>	RANEAID	Rare acquired neuroendocrine autoimmune diseases	11,999,916	Reserve

Area 2.1.1.1

Παρατήρηση

- Όλες οι προτάσεις που προτείνονται για χρηματοδότηση θα συμβάλουν σημαντικά στους στόχους του International Rare Disease Research Consortium (IRDiRC)

FP7-HEALTH-INNOVATION-1

Area 2.1.1, topics 2.1.1-2 & 2.1.1-3

Αποτέλεσμα αξιολόγησης:

- 2 θέματα
- Ενδεικτικός προϋπολογισμός €38 M
- Προϋπολογισμός χρηματοδότησης: €41 M
- Κατώτερη βαθμολογία 13.0
(2 reserve)

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 προκρίθηκαν	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
44	15	15	8	6 (40%)	2

Area 2.1.1

(2.1.1-2 & 2.1.1-3)

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14.5	<i>CENTRO DE INVESTIGACION PRINCIPE FELIPE</i>	STATegra	User-driven Development of Statistical Methods for Experimental Planning, Data Gathering, and Integrative Analysis of Next Generation Sequencing, Proteomics and Metabolomics data	5,999,551	5,999,551
2	14	<i>ACADEMISCH ZIEKENHUIS LEIDEN</i>	MIMOmics	Methods for Integrated analysis of Multiple Omics datasets	5,993,308	11,992,859
3	13.5	<i>UNIVERSITAETSKLINIKUM HEIDELBERG</i>	BestAgeing	Biomarker Research Alliance for Diagnosing Heart Disease in the Ageing European Population	10,906,368	22,899,227
4	13.5	<i>UNIVERSITAET BREMEN</i>	3D-MASSOMICS	Statistical methods for 3D imaging mass spectrometry in proteomics and metabolomics	2,796,882	25,696,109
5	13.5	<i>SERVICIO MADRILENO DE SALUD</i>	FRAILOMIC	Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative	11,999,552	37,695,661
6	13	<i>THE UNIVERSITY OF SHEFFIELD</i>	RADIANT	Rapid development and distribution of statistical tools for high-throughput sequencing data	3,672,362	41,368,023
7	12.5	<i>INSERM</i>	HOMAGE	Heart OMics in AGEing	12,000,000	Reserve
8	12	<i>FUNDACION PRIVADA CENTRE DE REGULACION GENOMICA</i>	SAFeuAGEING	Clinical validation of biological markers of risk and protection for major diseases affecting the elder population	1,993,495	Reserve

FP7-HEALTH-INNOVATION-1

Area 2.1.2

Αποτέλεσμα αξιολόγησης:

- **3 θέματα (systems medicine: systems biology driven by clinical needs)**
- **Ενδεικτικός προϋπολογισμός : €70 M**
- **Προϋπολογισμός για χρηματοδότηση: €76.65M**
- **Κατώτερη βαθμολογία 12.0**
(αρκετές σε reserve list)

Στάδιο 1 Υποβλήθηκαν	Στάδιο 1 προκρίθηκαν	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
70	32 (38%)	32	18	15 (47%)	3

Area 2.1.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14	ACADEMISCH ZIEKENHUIS GRONINGEN	RESOLVE	A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol	10,548,374	10,548,374
2	13.5	IMPERIAL COLLEGE	COMBI-BIO	Development of COMBINatorial BIOmarkers for subclinical atherosclerosis	2,991,075	13,539,449
3	13.5	INSERM	METACARDIS	Metagenomics in Cardiometabolic Diseases	11,999,992	25,539,441
4	13.5	MediMass Kutató, Fejleszt? és Szolgáltató Kft.	ISD	Intelligent Surgical Device	2,967,103	28,506,544
5	13.5	Creabilis	LSE	LSE TECHNOLOGY APPROACH TO GENERATE INNOVATIVE KINASE INHIBITOR DRUGS	1,449,681	29,956,225
6	13	HOSPICES CANTONNAUX CHUV	SysCLAD	Systems prediction of Chronic Lung Allograft Dysfunction	2,999,152	32,955,377
7	13	ROYAL COLLEGE OF SURGEONS	APO-DECIDE	Apoptosis Modelling for Treatment Decisions in Colorectal Cancer	2,999,763	35,955,140
8	13	Bionure Farma, SL	CombiMS	A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis	2,509,680	38,464,820
9	12.5	KAROLINSKA INSTITUTET	INFECT	Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures that Dictate Severity of Tissue Infection	11,913,591	50,378,411
10	12.5	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH	PRIAT	Profiling Responders In Antibody Therapies	2,967,485	53,345,896

Area 2.1.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
11	12	<i>INSTITUT GUSTAVE ROUSSY</i>	WINTHER	WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients.	2,998,355	56,344,251
12	12	<i>FORSCHUNGSZENTRUM JUELICH GMBH</i>	CASyM	Coordinating Action Systems Medicine – Implementation of Systems Medicine across Europe	2,997,178	59,341,429
13	12	<i>FUNDACIO CENTRE DE RECERCA EN SALUT INTERNATIONAL DE BARCELONA</i>	SysMalVac	Identifying correlates of protection to accelerate vaccine trials: systems evaluation of two models of experimentally-induced immunity to malaria	2,941,874	62,283,303
14	12	<i>GENOID MOLEKULARBIOLOGIAI KUTATO</i>	SYSTEMCERV	Systems biology approaches to cervical pre-cancer and cancer	2,368,884	64,652,187
15	12	<i>UNIVERSITY OF MANCHESTER</i>	Sysmed IBD	Systems medicine of chronic inflammatory bowel disease	11,999,998	76,652,185
16	12	<i>INSTITUTE OF SYSTEMS BIOLOGY LTD</i>	LipSys	Building a systems biology model of regulation of lipid metabolism applied for clinical stratification of combinatorial biomarkers of vascular and metabolic disease endpoints	1,968,931	Reserve
17	12	<i>TEKNOLOGIAN TUTKIMUSKESKUS VTT</i>	LIPPSY	Characterization and modelling of lipid metabolism as an early pathogenic link between obesity and its co-morbidities, with focus on Metabolic Syndrome and psychotic disorders	11,998,911	Reserve
18	12	<i>TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK - TNO</i>	LIFE-SAVER	Applied systems-based medicine for improved diagnosis and prognosis of type 2 diabetes and co-morbidities	11,999,633	Reserve

2. Translating research for human health

- 2.1 Integrating biological data and processes: large-scale data gathering, systems biology
- 2.2 **Research** on the brain and related diseases, **human development and ageing**
- 2.3 Translational research in major infectious diseases
- 2.4 Translational research in other major diseases

FP7-HEALTH-INNOVATION-1

Area 2.2.2 Human development and Ageing

Αποτελέσματα της αξιολόγησης

- 2 θέματα
- Ενδεικτικός προϋπολογισμός: €36 M
- Προϋπολογισμός της χρηματοδότησης: €30.9 M
- (όλες οι προτάσεις με βαθμολογία πάνω από τη βάση προτείνονται προς χρηματοδότηση)
- Χαμηλότερη βαθμολογία: 12.0

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 προκρίνονται	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
57	19 (33%)	18	6	6 (33%)	0

Area 2.2.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	13	<i>Academisch Medisch Centrum bij de Universiteit van Amsterdam</i>	HATICE	Healthy Aging Through Internet Counselling in the Elderly	5,824,039	5,824,039
2	13	<i>INSERM</i>	AgedBrainSYSBIO	SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING	6,000,000	11,824,039
3	12.5	<i>PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG</i>	PRIMA-eDS	Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in elderly populations by electronic Decision Support	4,618,520	16,442,559
4	12.5	<i>EUROPEAN MOLECULAR BIOLOGY LABORATORY</i>	SyStemAge	Early warning signals of ageing in human stem cells and age-related disorders	5,989,925	22,432,484
5	12	<i>UNIVERSITY COLLEGE CORK</i>	SENATOR	Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons	5,938,947	28,371,431
6	12	<i>TESAN S.P.A.</i>	CHROMED	Clinical tRials fOr elderly patients with Multiple Disease	2,563,531	30,934,962

Area 2.2.2

Παρατηρήσεις

- Οι προτάσεις θα συμβάλουν σημαντικά στο EIP “Active and Healthy Ageing”
- Αιτίες απόρριψης, έλλειψη πολύ καλά προσδιορισμένης της «υπόθεσης» (systems biology) ή αδυναμίες στο μεθοδολογικό σχεδιασμό (Κλινικές Δοκιμές)

2. Translating research for human health

- 2.1 Integrating biological data and processes: large-scale data gathering, systems biology
- 2.2 Research on the brain and related diseases, human development and ageing
- **2.3 Translational research in major infectious diseases**
- 2.4 Translational research in other major diseases

FP7-HEALTH-INNOVATION-1

Area 2.3.2 HIV/AIDS, malaria & TB

Αποτέλεσμα αξιολόγησης:

- 4 θέματα
- Ενδεικτικός προϋπολογισμός : €54 M
- Προϋπολογισμός χρηματοδότησης: €67.2M
- Κατώτερη βαθμολογία 13.0

Στάδιο 1 Υποβλήθηκαν	Στάδιο 1 προκρίθηκαν	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
183	53 (29%)	53	24	14 (26%)	10

Area 2.3.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14.5	<i>LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE</i>	TANDEM	Concurrent Tuberculosis and Diabetes Mellitus; unraveling the causal link, and improving care	5,998,496	5,998,496
2	14	<i>LABORATOIRE BIODIM</i>	HIVINNOV	Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions	6,000,000	11,998,496
3	14	<i>Academisch Medisch Centrum bij de Universiteit van Amsterdam</i>	PathCO	Pathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus	5,909,690	17,908,186
4	14	<i>IN2CARE BV INNOVATIVE INSECT CONTROL & APPLICATION RESEARCH</i>	MCD	A low cost Mosquito Contamination Device for sustainable malaria mosquito control	5,260,569	23,168,755
5	14	<i>HET KONINKLIJK INSTITUUT VOOR DE TROPEN</i>	COSMIC	Community-based scheduled screening and treatment of malaria in pregnancy for improved maternal and infant health: a cluster-randomized trial	2,997,218	26,165,973
6	13.5	<i>DRUGS FOR NEGLECTED DISEASES INITIATIVE FONDATION*DNDI</i>	AfriCoLeish	Care Package for Treatment and Control of Visceral Leishmaniasis in East Africa	3,000,000	29,165,973
7	13.5	<i>UNIVERSITY OF OXFORD</i>	PEACHI	Prevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens	4,388,813	33,554,786
8	13.5	<i>CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE</i>	HIT HIDDEN HIV	Paving the way toward HIV eradication/control	5,029,854	38,584,640
9	13.5	<i>UNIVERSITETET I BERGEN</i>	TRIGGER	King of hearts, joints and lungs; periodontal pathogens as etiologic factor in RA, CVD and COPD and their impact on treatment strategies.	5,982,363	44,567,003
10	13.5	<i>Academisch Medisch Centrum bij de Universiteit van Amsterdam</i>	COBRA	Co-morbidity in relation to Aids	5,998,760	50,565,763
11	13	<i>INSTITUT CATALA DE LA SALUT</i>	BERENICE	Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseaseE	2,998,217	53,563,980
12	13	<i>UNIVERSITY OF OXFORD</i>	MultiMalVax	A Multi-Stage Malaria Vaccine	6,000,000	59,563,980

Area 2.3.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
13	13	<i>KING'S COLLEGE LONDON</i>	MOTIF	Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery	5,818,937	65,382,917
14	13	<i>INSTITUTO DE SALUD CARLOS III</i>	AIM-HIV	Hydroxitirosol, a new generation of microbicides targeting HIV through antiviral and anti-inflammatory pathways	1,827,081	67,209,998
15	12.5	<i>UNIVERSITY COLLEGE CORK</i>	Supporting LIFE	Supporting Low-cost Intervention For disEase control	2,835,139	Reserve
16	12.5	<i>Kobenhavns Universitet</i>	PlacMaVac	Clinical development of a VAR2CSA-based placental malaria vaccine	5,935,545	Reserve
17	12.5	<i>ISTITUTO NAZIONALE TUMORI Fondazione Pascale</i>	MicroVac	Combinatorial effect of anti-HIV microbicides and vaccine by mucosal administration	3,829,737	Reserve
18	12.5	<i>Dilaforette AB</i>	ATSM	Novel Therapeutic for Adjunct Treatment of Severe Malaria; an innovative strategy	2,992,393	Reserve
19	12.5	<i>INSTITUT PASTEUR</i>	PALLERGO	The role of allergy in the severity of Plasmodium falciparum malaria	5,984,280	Reserve
20	12	<i>FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS</i>	PENTAHeP	HIV and Hepatitis co-infection in pregnant women, children and adolescents (PENTAHeP)	5,997,048	Reserve
21	12	<i>KATHOLIEKE UNIVERSITEIT LEUVEN</i>	SHINE	SME targeted development of HIV Inhibitors of Nuclear Entry	4,150,060	Reserve
22	12	<i>MEDICAL RESEARCH COUNCIL</i>	TUDIASSA	Tuberculosis and diabetes in sub Saharan Africa: burden, mechanisms and prevention	5,994,018	Reserve
23	12	<i>UNIVERSITY OF OXFORD</i>	PedVaccHIV-TB	A randomized phase I clinical trial of BCG.HIVconv, BCG+ChAdV63.HIVconv and MVA.HIVconv.85A vaccines against TB and breast milk transmission of HIV in BCG-naïve HIV-negative adults in Oxford	1,975,193	Reserve
24	12	<i>Medicines for Malaria Venture</i>	TREMAL	Discovery of novel transformational medicines for the prevention and treatment of malaria	4,095,788	Reserve

FP7-HEALTH-INNOVATION-2

2.3.0 Cross-cutting Infectious Diseases

Αποτέλεσμα της αξιολόγησης:

- 1 θέμα
- Ενδεικτικός προϋπολογισμός: € 36 M
- Προϋπολογισμός χρηματοδότησης: €26.7 M
- Κατώτερη βαθμολογία:12.0

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 προκρίθηκαν	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
55	19 (34%)	19	7	7 (37%)	0

Short list

Area 2.3.0

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	13.5	<i>ST GEORGE'S HOSPITAL MEDICAL SCHOOL</i>	NANOMAL	Development of a handheld antimalarial drug resistance diagnostic device using nanowire technology	3,992,150	3,992,150
2	13	<i>HET KONINKLIJK INSTITUUT VOOR DE TROPEN</i>	PreventIt	ASSURED Point-of-Care Device for Syphilis and HIV in Pregnant Women and New Born	2,097,373	6,089,523
3	13	<i>UNIVERSITY COLLEGE LONDON</i>	PATHSEEK	Automated Next Generation Sequencing for Diagnostic Microbiology	5,887,034	11,976,557
4	13	<i>OESTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN</i>	PIPAVIR	Detection of persistent infections by human papillomaviruses	3,615,666	15,592,223
5	13	<i>KUNGLIGA TEKNISKA HOEGSKOLAN</i>	ROUTINE	ROUTine diagnostic tool for Urinary Tract INfections caused by Esbl and carbapenamase producing bacteria	2,892,957	18,485,180
6	12.5	<i>UNIVERSITY COLLEGE LONDON</i>	RID-RTI	Rapid Identification of Respiratory Tract Infections	5,997,737	24,482,917
7	12	<i>UNIVERSIDAD POLITECNICA DE MADRID</i>	RaptaDiag	Rapid Aptamer based diagnostics for bacterial meningitis	2,174,570	26,657,487

FP7-HEALTH-INNOVATION-1

2.3.0 Cross-cutting Infectious Diseases

- **Θέμα 2.3.0-2 ERA-NET στα λοιμώδη νοσήματα**
- **Αποτέλεσμα: INFECT-ERA εγκρίθηκε**
- **Χρηματοδότηση: € 2M**

FP7-JPROG-2012-RTD

2.3.1 Antimicrobial Resistance

- **Topic 2.3.1-1: Coordination action in support to the Joint Programming Initiative on "The microbial challenge – an emerging threat to human health"**
- **Result: JPI AMR εγκρίθηκε**
- **Funding: € 2 M**

2. Translating research for human health

- 2.1 Integrating biological data and processes: large-scale data gathering, systems biology
- 2.2 Research on the brain and related diseases, human development and ageing
- 2.3 Translational research in major infectious diseases
- **2.4 Translational research in other major diseases**

FP7-HEALTH-INNOVATION-1

Area 2.4.3 - Diabetes & Obesity

Αποτελέσματα της αξιολόγησης:

- 2 θέματα
- Ενδεικτικός προϋπολογισμός : €36 M
- Προϋπολογισμός χρηματοδότησης: €32.5 M

Όλες οι προτάσεις με βαθμολογία πάνω από τη βάση χρηματοδοτούνται

- Κατώτερη βαθμολογία :12.5

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
40	13 (33%)	13	6	6 (46%)	0

Rank	Score	Topic	Acronym	Title	Coordinator	Proposed EU contrib.	Cumul. budget
1	13.5	2.4.3-2	DIABIL-2	Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes	<i>ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS</i>	5.900.000	5.900.000
2	13.5	2.4.3-1	EE-ASI	Beta cell preservation via antigen-specific immunotherapy in Type 1 Diabetes: Enhanced Epidermal Antigen Delivery Systems	<i>CARDIFF UNIVERSITY</i>	5.983.871	11.883.871
3	13	2.4.3-1	PCDIAB	A Portable bihormonal Closed Loop for Diabetes	<i>Academisch Medisch Centrum bij de Universiteit van Amsterdam</i>	4.335.284	16.219.155
4	12.5	2.4.3-1	REDDSTAR	Repair of Diabetic Damage by Stromal Cell Administration	<i>NATIONAL UNIVERSITY OF IRELAND, GALWAY</i>	5.894.460	22.113.615
5	12.5	2.4.3-1	SPIDIMAN	Single-Port Insulin Infusion for Improved Diabetes Management	<i>JOANNEUM RESEARCH FORSCHUNGSGESELLSCH AFT MBH</i>	4.943.407	27.057.022
6	12.5	2.4.3-1	BIOSID	A bioartificial pancreas to treat type 1 diabetes: optimization of cell survival and function in preclinical and clinical phases	<i>Centre européen d'étude du Diabète</i>	5.469.666	32.526.688

FP7-HEALTH-INNOVATION-1

Area 2.4.4

Αποτέλεσμα αξιολόγησης:

- **3 θέματα**
- **Ενδεικτικός προϋπολογισμός: €70 M**
- **Προϋπολογισμός χρηματοδότησης: €68 M**
(χρηματοδοτούνται όλες οι προτάσεις με βαθμολογία πάνω από τη βάση)
- **Κατώτερη βαθμολογία : 12.0**

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
76	37 (49%)	36	15	15 (42%)	0

Short list

Area 2.4.4

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	15	<i>Royal Liverpool and Broadgreens University Hospitals Trust</i>	DevelopAKUre	Clinical Development of Nitisinone for Alkaptonuria	5,999,999	5,999,999
2	14.5	<i>STICHTING KATHOLIEKE UNIVERSITEIT</i>	OPTIMISTIC	Observational Prolonged Trial In Myotonic dystrophy type 1 to Improve QoL-Standards, a Target Identification Collaboration	3,000,000	8,999,999
3	14	<i>JUSTUS-LIEBIG-UNIVERSITAET GIESSEN</i>	DeSScipher	To decipher the optimal management of systemic sclerosis	2,999,835	11,999,834
4	14	<i>ISTITUTO SUPERIORE DI SANITA</i>	RARE-Bestpractices	Platform for sharing best practices for management of rare diseases	2,000,000	13,999,834
5	13.5	<i>Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas - CIEMAT</i>	EUROFANCOLEN	Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action	5,380,170	19,380,004
6	13	<i>LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN</i>	chILD-EU	Orphans Unite: chILD better together – European Management Platform for Childhood Interstitial Lung Diseases	3,000,000	22,380,004
7	13	<i>Prophylix Pharma AS</i>	PROFNAIT	Development of a prophylactic treatment for the prevention of fetal/neonatal alloimmune thrombocytopenia	6,000,000	28,380,004

Short list Area 2.4.4

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
8	12.5	<i>GOETEBORGS UNIVERSITET</i>	PREVENTROP	New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP)	5,990,236	34,370,240
9	12.5	<i>WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER</i>	BESTCILIA	Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia	2,993,676	37,363,916
10	12.5	<i>NOVIMMUNE SA</i>	FIGHT-HLH	First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH	5,946,262	43,310,178
11	12.5	<i>UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ</i>	STRONG	European Consortium for the Study of a Topical Treatment of Neovascular Glaucoma	5,979,974	49,290,152
12	12.5	<i>Società Industria Farmaceutica Italiana S.p.A.</i>	ODAK	Orphan Drug for Acanthamoeba Keratitis	4,050,255	53,340,407
13	12	<i>Oy Faron Pharmaceuticals Ltd</i>	Traumakine	Interferon-beta treatment of acute respiratory distress syndrome (ARDS)	6,000,000	59,340,407
14	12	<i>FONDAZIONE TELETHON</i>	MeuSIX	Clinical trial of gene therapy for MPS VI - a severe lysosomal storage disorder	5,995,041	65,335,448
15	12	<i>CHARITE - UNIVERSITAETSMEDIZIN BERLIN</i>	DSD-Life	Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD)	2,999,956	68,335,404

Area 2.4.4

Παρατηρήσεις

- Συμμετοχή πολλών κρατών: **EU (17 MS), Switzerland, Norway, USA, Argentina, New Zealand, Australia, Israel, Turkey, Russia, Ukraine, Georgia, Armenia**
- Χρηματοδοτούνται και οι 15 προτάσεις που βαθμολογήθηκαν πάνω από τη βάση

FP7-HEALTH-INNOVATION-2
Area 2.4.5 - Technological
approaches to combating sensory impairments

Αποτέλεσμα αξιολόγησης για άλλες χρόνιες παθήσεις:

- 1 θέμα
- Ενδεικτικός προϋπολογισμός: €30 M
- Προϋπολογισμός χρηματοδότησης: €31.9 M
- Κατώτερη βαθμολογία: 12

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	Reserve
24	13 (54%)	12	7	7 (58%)	0

Short list

2.4.5-1

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	13	<i>Alma IT Systems, S.L.</i>	HEAR-EU	High-resolution image-based computational inner ear modelling for surgical planning of cochlear implantation	3,558,950	3,558,950
2	12.5	<i>EBERHARD KARLS UNIVERSITAET TUEBINGEN</i>	DRUGSFORD	Preclinical development of drugs and drug delivery technology for the treatment of inherited photoreceptor degeneration	4,971,428	8,530,378
3	12.5	<i>TEL AVIV UNIVERSITY</i>	VISION	Prolonged inhibition of semaphorine3a pathway via a bio-degradable implant towards a better therapy for visual sensory impairments	5,661,253	14,191,631
4	12.5	<i>NsGene A/S</i>	NeuEar	Neurotrophic Cochlear Implant for Severe Hearing Loss	5,843,872	20,035,503
5	12	<i>UNIVERSITY COLLEGE LONDON</i>	ABCIT	Advancing Binaural Cochlear Implant Technology	5,649,016	25,684,519
6	12	<i>AFFICHEM SA</i>	AFHELO	Preclinical proof of concept of AF243 potency to prevent and/or treat sensorineural hearing loss	2,796,376	28,480,895
7	12	<i>UNIVERSIDAD DE CASTILLA - LA MANCHA</i>	PROHEARING	A novel micronutrient-based strategy to prevent hearing impairments: test and road to market for age-related hearing loss and preservation of residual hearing	5,096,600	33,577,495

FP7-HEALTH-INNOVATION-1

Area 2.4.5 – Other Chronic Diseases

Αποτελέσματα αξιολόγησης:

- **1 θέμα**
- **Ενδεικτικός προϋπολογισμός: €12 Μ**
- **Προϋπολογισμός χρηματοδότησης: €23.8 Μ**
(4/5 προτείνονται προς χρηματοδότηση)
- **Κατώτερη βαθμολογία :12.5**

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	Reserve
35	11 (31%)	11	5	4 (36%)	1

Short list

2.4.5-2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	13	<i>OLINK AB</i>	IBD-CHARACTER	Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study	5,989,346	5,989,346
2	13	<i>THE UNIVERSITY OF NOTTINGHAM</i>	D-BOARD	Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases	5,996,451	11,985,797
3	13	<i>THE UNIVERSITY OF EDINBURGH</i>	IBD-BIOM	Diagnostic and prognostic biomarkers for inflammatory bowel disease	5,999,611	17,985,408
4	12.5	<i>THE UNIVERSITY OF BIRMINGHAM</i>	Euro-TEAM	Towards Early diagnosis and biomarker validation in Arthritis Management	5,777,400	23,762,808
5	12	<i>WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER</i>	MIAMI	Monitoring innate immunity in arthritis and mucosal inflammation	5,703,145	29,465,953

3. Optimising the delivery of healthcare

- 3.1 Translating the results of clinical research
- 3.2 Quality, efficiency and solidarity of healthcare systems
- 3.3 Health promotion and prevention
- 3.4 International public health & health systems

FP7-HEALTH-INNOVATION-1

Area 3.2 Quality, efficiency and solidarity of healthcare systems

Αποτέλεσμα της αξιολόγησης:

- 3 θέματα
- Ενδεικτικός προϋπολογισμός: €39 M
- Προϋπολογισμός χρηματοδότησης: €40 M
- Κατώτερη βαθμολογία :12.0

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
165	38 (23%)	37	16	14 (38%)	2

Short-list

Area 3.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14	<i>TRINITY COLLEGE DUBLIN</i>	OptiBIRTH	Improving the organisation of maternal health service delivery, and optimising childbirth, by increasing vaginal birth after caesarean section (VBAC) through enhanced women-centred care	2,999,546	2,999,546
2	13.5	<i>LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE</i>	ADVANCE_HTA	Advancing and strengthening the methodological tools and practices relating to the application and implementation of Health Technology Assessment (HTA)	2,999,805	5,999,351
3	13.5	<i>DUBLIN CITY UNIVERSITY</i>	In MINDD	Innovative Midlife Intervention for Dementia deterrence	2,950,562	8,949,913
4	13.5	<i>VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG</i>	IBenC	Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care	2,999,198	11,949,111
5	13.5	<i>UNIVERSITE CATHOLIQUE DE LOUVAIN</i>	IABETES LITERAC	Enhancing the (cost-)effectiveness of diabetes self-management education: A comparative assessment of different educational approaches and conditions for successful implementation	2,980,432	14,929,543
6	13	<i>STICHTING KATHOLIEKE UNIVERSITEIT</i>	InSup-C	Patient centered palliative care pathways in advanced cancer and chronic disease	2,998,419	17,927,962
7	13	<i>UNIVERSITA COMMERCIALE 'LUIGI BOCCONI'.</i>	MedtechTA	Methods for Health Technology Assessment of Medical Devices: a European Perspective	2,055,134	19,983,096
8	13	<i>UNIVERSITY OF SHEFFIELD</i>	INNOVAGE	Social Innovations Promoting Active and Healthy Ageing	2,993,457	22,976,553

Short-list Area 3.2

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
9	13	<i>NATIONAAL INSTITUUT VOOR GEZONDSHEIDSBEVORDERING EN ZIEKTEPREVENTIE</i>	IROHLA	Intervention Research On Health Literacy among Ageing population	2,998,923	25,975,476
10	12.5	<i>UNIVERSITAET BREMEN</i>	INTEGRATE	Integrated health technology assessment for evaluating complex technologies	2,976,001	28,951,477
11	12.5	<i>UNIVERSIDAD DE NAVARRA</i>	INTEGRATE	Benchmarking Integrated Care for better Management of Chronic and Age-related Conditions in Europe	2,898,468	31,849,945
12	12.5	<i>UNIVERSITAET BREMEN</i>	REHAB4LIFE	Engaging Game-based Home Rehabilitation for Improved Quality of Life	2,367,090	34,217,035
13	12	<i>THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN</i>	MUNROS	Health Care Reform: the iMpact on practice, oUtcomes and costs of New roles for health pROfeSsionals	2,999,685	37,216,720
14	12	<i>FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA</i>	AdHopHTA	Adopting Hospital Based Health Technology Assessment in EU	2,828,460	40,045,180
15	12	<i>FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA</i>	?PAD	MULTisensory-Microactuated Personal Assistive Device	2,523,002	Reserve
16	12	<i>TECHNISCHE UNIVERSITAET DORTMUND</i>	SIPI OPE	Social innovation promotion inclusion for older people with chronic mental health conditions in Europe: The role of health and social care	2,237,398	Reserve

FP7-HEALTH-INNOVATION-1

Area 3.4 International public health & health systems

Αποτελέσματα αξιολόγησης:

- 1 θέμα
- Ενδεικτικός προϋπολογισμός: €18 M
- Προϋπολογισμός χρηματοδότησης: €17.9 M
- Κατώτερη βαθμολογία :12.0

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
66	8 (12%)	8	3	3 (38%)	0

Short list Area 3.4

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14.5	<i>LIVERPOOL SCHOOL OF TROPICAL MEDICINE</i>	REACHOUT	Reaching out and linking in: Health systems and close-to-community services	5,999,899	5,999,899
2	14	<i>CONSORCI DE SALUT I D'ATENCIO SOCIAL DE CATALUNYA</i>	Equity-LA II	The impact of alternative care integration strategies on Health Care Networks' performance in different Latin American health systems	5,926,937	11,926,836
3	12	<i>KING'S COLLEGE LONDON</i>	EMERALD	Emerging mental health systems in low- and middle-income countries	5,994,028	17,920,864

4. Other actions across the health theme

- **4.1 Coordination and Support Actions**
across the theme
- 4.2 Responding to EU policy needs

Area 4.1 – Coordination and Support Actions

Αποτελέσματα αξιολόγησης:

- 6 θέματα
- Ενδεικτικός προϋπολογισμός: €6 M
- Προϋπολογισμός χρηματοδότησης: €11 M
- Κατώτερη βαθμολογία :12.0
(3 reserve)

Στάδιο 1 υποβλήθηκαν	Στάδιο 1 εγκρίθηκαν για αξιολόγηση	Στάδιο 2 Αξιολογήθηκαν	Πάνω από τη βάση	Short-listed (success rate)	reserve
58	22 (38%)	22	14	11 (50%)	3

Short list Area 4.1

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
1	14	<i>YOURIS.COM</i>	HIGHLIGHT	Highlighting EU-funded Health research results via TV media and the internet	999,490	999,490
2	14	<i>CHANCEL LIMITED</i>	ERFIP2013	2013 Epilepsy Research Forum	100,000	1,099,490
3	13.5	<i>INNO AG</i>	Health-2-Market	Advanced Services and Training Actions for the IPR Management and Business Exploitation of the EU-funded Research Results in Health/life sciences	1,999,785	3,099,275
4	13.5	<i>PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE</i>	Go4Health	Formulating new Goals for global health, and proposing new Governance for global health that will allow the achievement of these goals	1,998,222	5,097,497
5	13	<i>UNIVERSITY OF LIVERPOOL</i>	COMET	The COMET (Core Outcome Measures in Effectiveness Trials) Initiative	497,368	5,594,865
6	13	<i>TRINITY COLLEGE DUBLIN</i>	ASAPS	Sharing Age A Sharing Approach to Promoting Science	999,001	6,593,866
7	12.5	<i>VDI/VDE INNOVATION + TECHNIK GMBH</i>	NANOMED2020	Enabling the European Nanomedicine Area until 2020	499,649	7,093,515
8	12.5	<i>Societe Europeenne de Cardiologie</i>	CardioScape	A survey of the European cardiovascular research landscape and recommendations for future research strategy	487,380	7,580,895
9	12.5	<i>AIT Austrian Institute of Technology GmbH</i>	PHS Foresight	Personal Health Systems Foresight	485,339	8,066,234
10	12	<i>Istituto di Rceiherche Farmacologiche MARIO NEGRI</i>	ECRAN	European Communication on Research Awareness Needs	916,044	8,982,278
11	12	<i>INSERM - TRANSFERT SA</i>	ENTENTE	European Network of Knowledge Transfer in Health	1,999,985	10,982,263

rank	score	Coordinator	Acronym	Title	Proposed budget (€)	Cumulative budget (€)
12	13	<i>UNIVERSITY COLLEGE LONDON</i>	BetterHealthDGs	Evidence based options for health-related development goals beyond 2015 based on expert analysis of the	1,953,233	Reserve
13	12.5	<i>TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY.</i>	TIP4Health	Technology transfer and IP training activities for the successful exploitation of research results	1,897,808	Reserve
14	12	<i>ESCUELA ANDALUZA DE SALUD PUBLICA SA</i>	GHF beyond 2015	Analysis of the present health-MDG framework and proposal for a new framework on global health post-2015	1,999,685	Reserve

Ελληνική Συμμετοχή Innov-1

RD-Connect	Πανεπιστήμιο Πατρών
EUROSTAM	Περ.Νοσοκομείο Γεννηματάς
CombiMS	Προτάτουανς Α.Ε.
Bestcilia	Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
Combi-bio	Πανεπιστήμιο Ιωαννίνων
Health-2-Market	International Environment and Quality Services North Greece S.A.
Resolve	Ίδρυμα Τεχνολογίας και Έρευνας
RiskyCAD	Ίδρυμα Ιατροβιολογικών Ερευνών Ακαδημίας Αθηνών
RiskyCAD	Περσίδης Α.Ε.
IROHLA	Institute of Preventive Medicine Environmental and Occupational Health

Ελληνική Συμμετοχή Innov-1

IROHLA	Cambo Industries Digital Ltd
STRATegra	Ίδρυμα Τεχνολογίας και Έρευνας
BestAgeing	Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
THALAMOSS	Ίδρυμα Ιατροβιολογικών Ερευνών Ακαδημία Αθηνών
THALAMOSS	Λαϊκό Νοσοκομείο Αθηνών

Ελληνική Συμμετοχή Innov-2

- ΡΙΡΑΝΙΡ
- Πανεπιστήμιο Πατρών

- **Πληροφορίες**
- **FP7 Health web site:**
<http://cordis.europa.eu/fp7/health> **Support:**
<http://cordis.europa.eu/fp7/health/support>
[en.html](http://cordis.europa.eu/fp7/health/support) **Registration as an Expert:**
<https://cordis.europa.eu/emfp7/>
- **FitForHealth:** www.fitforhealth.eu **EC projects**
- **database:** www.healthcompetence.eu

- Δρ. Σ. Κολυβά
- Ελληνικό Ινστιτούτο Παστέρ
- Τηλ. 210-6478883
- s.kolyva@pasteur.gr